The triple-agonist retatrutide reduced a key marker of kidney damage by up to 37% and improved kidney filtration in people with obesity, suggesting kidney-protective benefits beyond weight loss.
−37% UACR reductionRetatrutide 12 mg reduced this marker of kidney damage versus placebo in people with type 2 diabetes at 36 weeks
What the researchers found
Retatrutide, the triple-receptor agonist (GIP/GLP-1/glucagon), showed kidney-protective effects in two phase 2 trials. In people with type 2 diabetes, retatrutide 12 mg reduced urine albumin-to-creatinine ratio (UACR) by 37% versus placebo at 36 weeks, though kidney filtration rate (eGFR) was unchanged. In people with obesity but no diabetes, retatrutide 12 mg reduced UACR by 31.5% and increased eGFR by 8.5 ml/min/1.73m² at 48 weeks.
The eGFR improvement in the obesity group was confirmed using three different measurement methods (creatinine-based, cystatin C-based, and combined), strengthening confidence in the finding. However, since most participants had normal baseline albuminuria, the absolute reductions were modest.
Why it matters
Kidney disease is a major complication of both obesity and type 2 diabetes, and current treatments have limited options. This is the first data showing that a triple-agonist peptide (targeting GIP, GLP-1, and glucagon receptors simultaneously) may protect kidneys — not just through weight loss, but potentially through direct renal benefits. If confirmed in dedicated kidney outcome trials, retatrutide could add kidney protection to its weight loss and metabolic benefits.
The numbers in context
n=619 total · T2D group (n=281): UACR −37% vs placebo at 36 weeks · Obesity group (n=338): UACR −31.5%, eGFR +8.5 ml/min/1.73m² vs placebo at 48 weeks · Dose range: 0.5-12 mg · Baseline eGFR: ~90-91 ml/min/1.73m²
How the study worked
Post hoc analysis of two randomized, placebo-controlled phase 2 trials of retatrutide. One enrolled participants with T2D (36 weeks), the other enrolled those with overweight/obesity without T2D (48 weeks). Kidney parameters measured included UACR, eGFR from creatinine, eGFR from cystatin C, and combined eGFR. All participants had baseline eGFR ≥45 ml/min/1.73m². The T2D study included dulaglutide 1.5 mg as an active comparator.
Who was studied
Adults with type 2 diabetes (n=281) or overweight/obesity without diabetes (n=338), all with eGFR ≥45 ml/min/1.73m²
What this study cannot tell us
Post hoc analysis — kidney outcomes were not the primary endpoint of either trial. Most participants had normal baseline albuminuria, limiting ability to assess effects in people with established kidney disease. Relatively short duration (36-48 weeks). Not powered specifically for kidney endpoints. The eGFR improvement in obesity but not T2D needs explanation.
How to read the evidence
This is a post hoc analysis of two well-designed randomized controlled trials, which is stronger than observational data but weaker than a dedicated kidney outcome trial. The consistency across measurement methods (creatinine, cystatin C, combined eGFR) strengthens the findings.
When this study was published
Published in 2025, this is very recent data from an active drug development program. Retatrutide is currently in phase 3 trials, and dedicated kidney outcome studies may follow based on these promising signals.
The bigger picture
GLP-1 agonists like semaglutide have already shown kidney benefits, but retatrutide is the first triple-agonist to demonstrate renal effects. The addition of glucagon receptor agonism — which was initially a concern because glucagon can raise blood sugar — may actually contribute to kidney protection through mechanisms not yet fully understood. This positions retatrutide in an increasingly competitive field where metabolic drugs are expected to deliver benefits beyond weight loss.
Questions still open
- Why did retatrutide improve eGFR in the obesity group but not in the T2D group?
- Would these kidney benefits be larger in patients with more advanced kidney disease at baseline?
- How does retatrutide's kidney protection compare to dedicated kidney drugs like SGLT2 inhibitors or finerenone?
Common questions
What is retatrutide and how is it different from semaglutide?
Does retatrutide actually improve kidney function or just slow decline?
Read the original research
The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.
Kidney international reports, 10(6), 1980-1992
Citation
Heerspink, Hiddo J L; Lu, Zeqing; Du, Yu; Duffin, Kevin L; Coskun, Tamer; Haupt, Axel; Hartman, Mark L. (2025). The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.. Kidney international reports, 10(6), 1980-1992. https://doi.org/10.1016/j.ekir.2025.03.049